Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 2, 2012, Pages 179-183

  Ali, Aamir ^a   An, So Jung ^b   Cui, Changfa ^b,c   Haque, Abdul ^a   Carbis, Rodney ^b  

^a NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

^b International Vaccine Institute   (South Korea)

^c Chengdu Institute of Biological Products   (China)

Author keywords

Conjugate vaccine; Diphtheria toxoid; Polysaccharide antigen; S. Typhi; Typhoid

Indexed keywords

ADIPIC ACID; ADIPIC ACID DIHYDRAZIDE; DIPHTHERIA TOXOID; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; O SPECIFIC POLYSACCHARIDE ADIPIC ACID DIHYDRAZIDE DIPHTHERIA TOXOID; POLYSACCHARIDE; TYPHOID VACCINE; UNCLASSIFIED DRUG; BACTERIUM LIPOPOLYSACCHARIDE; SALMONELLA TYPHI O SPECIFIC POLYSACCHARIDE ADIPIC ACID DIHYDRAZIDE DIPHTHERIA TOXOID CONJUGATE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; SALMONELLA TYPHI; TREATMENT OUTCOME; TYPHOID FEVER; VACCINE PRODUCTION; DRUG SCREENING; DRUG SYNTHESIS; INFECTION PREVENTION; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; CARRIER PROTEINS; DIPHTHERIA TOXOID; FEMALE; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; O ANTIGENS; SALMONELLA TYPHI; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINES, CONJUGATE;

EID: 84858203097     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.2.18350     Document Type: Article

References (41)

1. Robbins JB, Schneerson R, Szu SC, Pozsgay V. Bacterial polysaccharide-protein conjugate vaccines. Pure Appl Chem 1999; 71:745-54; http://dx.doi.org/10.1351/pac199971050745
2. Robbins JB, Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis 1990; 161:821-32; PMID:2182727; http://dx.doi.org/10.1093/infdis/161.5.821
3. Jones C. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An Acad Bras Cienc 2005; 77:293-324; PMID:15895165; http://dx.doi.org/10.1590/S0001-37652005000200009
4. Goldblatt D. Recent developments in bacterial conjugate vaccines. J Med Microbiol 1998; 47:563-7; PMID:9839559; http://dx.doi.org/10.1099/00222615-47-7- 563
5. Finn A. Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 2004; 70:1-14; PMID:15339854; http://dx.doi.org/10.1093/bmb/ldh021
6. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. Clin Infect Dis 2010; 50:241-6; PMID:20014951; http://dx.doi.org/10.1086/649541
7. Cui C, Carbis R, An SJ, Jang H, Czerkinsky C, Szu SC, et al. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 2010; 17:73-9; PMID: 19889941; http://dx.doi.org/10.1128/CVI.00266-09
8. StormonMO, McIntyre PB,Morris J, Fasher B. Typhoid fever in children: diagnostic and therapeutic difficulties. Pediatr Infect Dis J 1997; 16:713-4; PMID:9239778; http://dx.doi.org/10.1097/00006454-199707000-00016
9. Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 2004; 72:6586-8; PMID:15501790; http://dx.doi.org/10.1128/IAI.72.11. 6586-6588.2004
10. Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999; 67:5806-10; PMID:10531232
11. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-9; PMID:11320385; http://dx.doi.org/10.1056/ NEJM200104263441701
12. Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007; 45(Suppl 1):S20-3; PMID:17582563; http://dx.doi.org/10.1086/518135
13. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull World Health Organ 1994; 72:957-71; PMID:7867143
14. Hale C, Bowe F, Pickard D, Clare S, Haeuw JF, Powers U, et al. Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis. Vaccine 2006; 24: 4312-20; PMID:16600446; http://dx.doi.org/10.1016/j.vaccine.2006.03. 002
15. Gupta RK, Egan W, Bryla DA, Robbins JB, Czu SC. Comparative Immunogenicity of Conjugates Composed of Escherichia coli O111 O-Specific Polysaccharide, Prepared by Treatment with Acetic Acid or Hydrazine, Bound to Tetanus Toxoid by Two Synthetic Schemes. Infect Immun 1995; 63:2805-10; PMID:7542631
16. Chu CY, Liu BK, Watson D, Szu SS, Bryla D, Shiloach J, et al. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun 1991; 59:4450-8; PMID:1937803
17. Konadu E, Donohue-Rolfe A, Calderwood SB, Pozsgay V, Shiloach J, Robbins JB, et al. Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice. Infect Immun 1999; 67:6191-3; PMID:10531288
18. Aron L, Di Fabio J, Cabello FC. Salmonella typhi O:9,12 polysaccharide-protein conjugates: characterization and immunoreactivity with pooled and individual normal human sera, sera from patients with paratyphoid A and B and typhoid fever, and animal sera. J Clin Microbiol 1993; 31:975-8; PMID:7681853
19. WHO technical report series, no. 840. Requirements for Vi polysaccharide typhoid vaccine. WHO, Geneva, Switzerland. 1994.
20. Hessel L, Debois H, Fletcher M, Dumas R. Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 1999; 18: 609-20; PMID:10534182; http://dx.doi.org/10.1007/s100960050361
21. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346-53; PMID:15298225
22. Vollaard AM, Ali S, van Asten HA, Widjaja S, Visser LG, Surjadi C, et al. Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia. JAMA 2004; 291:2607-15; PMID:15173152; http://dx.doi.org/10.1001/jama.291.21.2607
23. Ali A, Haque A, Sarwar Y, Mohsin M, Bashir S, Tariq A. Multiplex PCR for differential diagnosis of emerging typhoidal pathogens directly from blood samples. Epidemiol Infect 2009; 137:102-7; PMID:18413005; http://dx.doi.org/10. 1017/S0950268808000654
24. Baker S, Sarwar Y, Aziz H, Haque A, Ali A, Dougan G, et al. Detection of Vi-negative Salmonella enterica serovar typhi in the peripheral blood of patients with typhoid fever in the Faisalabad region of Pakistan. J Clin Microbiol 2005; 43:4418-25; PMID:16145086; http://dx.doi.org/10.1128/JCM.43.9. 4418-4425.2005
25. Arnold WS, Harcus AW, St Clair Roberts J, Ward AE. Experience with Vi typhoid capsular polysaccharide vaccine in the U.K. J Infect 1992; 25:63-6; PMID: 1522324; http://dx.doi.org/10.1016/0163-4453(92) 93537-Z
26. Garmory HS, Brown KA, Titball RW. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev 2002; 26:339-53; PMID:12413664
27. Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. Typhoid fever vaccines: systematic review and metaanalysis of randomised controlled trials. Vaccine 2007; 25:7848-57; PMID:17928109; http://dx.doi.org/10.1016/j.vaccine. 2007.08.027
28. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340:592-4; PMID:1355165; http://dx.doi.org/10.1016/0140- 6736(92)92117-X
29. Kieny MP, LaForce FM. The promise of conjugate vaccines for Africa. Vaccine 2007; 25(Suppl 1):A108-10; PMID:17548136; http://dx.doi.org/10.1016/j. vaccine.2007.05.001
30. Konadu E, Robbins JB, Shiloach J, Bryla DA, Szu SC. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines. Infect Immun 1994; 62:5048-54; PMID:7927787
31. Zuñiga J, Lillo L, Shin JJ, Machavarapu RL, Quiroga T, Goycoolea M, et al. Salmonella enterica serovar Typhi O:1,9,12 polysaccharide-protein conjugate as a diagnostic tool for typhoid fever. J Clin Microbiol 2005; 43:4545-50; PMID:16145105; http://dx.doi.org/10.1128/JCM.43.9.4545-4550.2005
32. Acosta CJ, Hong-hui Y, Ning W, Qion G, Qun D, Xiaolei M, et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up. Vaccine 2005; 23:5618-23; PMID: 16098635; http://dx.doi.org/10.1016/j.vaccine.2005.06.035
33. Tsai CM. The analysis of lipopolysaccharide (endotoxin) in meningococcal polysaccharide vaccines by silver staining following SDS-polyacrylamide gel electrophoresis. J Biol Stand 1986; 14:25-33; PMID:2420803; http://dx.doi.org/ 10.1016/S0092-1157(86)80006-3
34. Levin J, Bang FB. The role of endotoxin in the extracellular coagulation in the Limulus. Bull Johns Hopkins Hosp 1964; 115:265-74; PMID:14209047
35. Konadu E, Shiloach J, Bryla DA, Robbins JB, Szu SC. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls. Infect Immun 1996; 64:2709-15; PMID:8698499
36. Chu C, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharideprotein conjugates. Infect Immun 1983; 40:245-56; PMID:6601061
37. Scott TA, Melvin EH. Determination of dextran with anthrone. Anal Chem 1953; 25:1656-61; http://dx.doi.org/10.1021/ac60083a023
38. Ouchterlony O, Nilson LA. Immunodiffusion and Immunoelectrophoresis. In: Weir DM, Herzenberg LA, Blackwell C, Herzenberg LA, eds. Handbook of Experimental Immunologyed. Oxford: Blackwell, 1986:32.1-32.50.
39. Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993; 61:1023-32; PMID: 8432585
40. Szu SC, Li XR, Schneerson R, Vickers JH, Bryla D, Robbins JB. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect Immun 1989; 57: 3823-7; PMID:2807549
41. Plikaytis BD, Holder PF, Carlone GM. Program ELISA for Windows user's manual, version 1.00. Centers for Diease Control and Prevention, Atlanta, GA. 1996.